Pariblieva 150mg

Pariblieva 150mg Tablet is classified as a cancer treatment within the PARP (poly [adenosine diphosphate-ribose] polymerase inhibitor) inhibitors category, featuring the active ingredient Olaparib. It is utilized for the treatment of ovarian, breast, pancreatic, and prostate cancers. This medication may be administered on its own or in conjunction with other anticancer therapies.

It is advised against taking Pariblieva 150mg Tablet if you have an allergy to the active ingredient or any other components of the medication. If you experience symptoms such as breathlessness, chest pain, rapid heartbeat, fever, cough, or wheezing, contact your doctor immediately. Your healthcare provider will perform blood tests prior to and monthly throughout the treatment, as this medication may lower the levels of RBC, WBC, and platelets. Inform your healthcare provider before starting treatment if you have been diagnosed with any issues related to your lungs, liver, heart, or kidneys.

This medication is not recommended for use during pregnancy due to the potential risk of harm to the fetus and the possibility of miscarriage. Therefore, it is advisable for women of childbearing age to take a pregnancy test before starting this medication. It is also recommended to continue using birth control for at least six months after completing treatment. While undergoing treatment, breastfeeding is not recommended as it is unclear whether Pariblieva 150mg Tablet can be transferred into breast milk. Men are advised against donating sperm for at least three months following the completion of treatment. It is essential to inform your doctor about all medications you are currently taking, including prescription drugs, over-the-counter medications, vitamins, and supplements.